TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03654105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine
Description: Cytisine administration will be randomized 1:1 in standard (40 days)and prolonged treatment (84 days).~Subjects will be educated on how to take the product and informed about possible adverse effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine
Description: Cytisine administration will be randomized 1:1 in standard (40 days)and prolonged treatment (84 days).~Subjects will be educated on how to take the product and informed about possible adverse effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: The treatment will consist of Acetylsalicylic acid at 100mg once a day
Study: NCT01701128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking on treadmill
Description: 3 sessions/week, 24 weeks. The heart rate does not exceed 75% of maximum heart rate (220-age) of the participant and that blood pressure does not exceed 250/115 mmHg. During the first week, the TT velocity was adjusted to 80% of preferential walking speed of the participant. The following week, the participant was encouraged to reach 90% and 100% in the third week. From the fourth week, subjects in the Speed TT had an increase in speed, depending on exercise tolerance of each participant. The TT velocity was increased by 0,2 km/h when the participant reached criteria.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking on treadmill
Description: 3 sessions/week, 24 weeks. The heart rate does not exceed 75% of maximum heart rate (220-age) of the participant and that blood pressure does not exceed 250/115 mmHg. During the first week, the TT velocity was adjusted to 80% of preferential walking speed of the participant. The following week, the participant was encouraged to reach 90% and 100% in the third week. From the fourth week, the TT velocity was increased by 0,2 km/h or the incline of the walking surface of TT was increased by 1% alternately when the progression criteria were met.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Training of the control group was characterized by light intensity exercises. For the first three months, participants performed regular exercise involving full range of motion to enhance their flexibility. For the last three months of the training programme, participants learned elements of Tai Chi and rhythmic movements of latin dance. Participants attended two 1-h supervised sessions per week and were asked to perform each week a third session at home, based on instructions in a document offered to the control group participants
Study: NCT00870922

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active release techniques
Description: Participants will receive ART and have Therabite (mouth opening) and pain (VAS) measured before and after ART
Study: NCT02518685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TransPyloric Shuttle

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Lifestyle Counseling
Description: The goal of lifestyle modification counseling is to promote adherence to a reduced calorie diet, increased physical activity and to recommend behavioral modification strategies.
Study: NCT03654105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: The treatment will consist of Acetylsalicylic acid at 100mg once a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Modification and Physical Activity Increase
Description: It will be proposed:~1. an optimal diet with the aim of favoring control of weight, abdominal fat and adequate nutritional status without increasing the levels of IGF-I and inflammatory factors or glycemic peaks, with periodic verification of the results~2. a regular and sustainable physical activity program with periodic verification of the results.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Modification and Physical Activity Increase
Description: It will be proposed:~1. an optimal diet with the aim of favoring control of weight, abdominal fat and adequate nutritional status without increasing the levels of IGF-I and inflammatory factors or glycemic peaks, with periodic verification of the results~2. a regular and sustainable physical activity program with periodic verification of the results.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: early lung cancer detection
Description: standard treatment for early lung cancer detection with ultra low dose CT

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: early lung cancer detection
Description: standard treatment for early lung cancer detection with ultra low dose CT

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: early lung cancer detection
Description: standard treatment for early lung cancer detection with ultra low dose CT

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: early lung cancer detection
Description: standard treatment for early lung cancer detection with ultra low dose CT

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: spirometry with CO test
Description: spirometry with CO test
Study: NCT02456259

Intervention type: PROCEDURE
Intervention: Neck cannula insertion
Description: Neck cannula insertion is necessary for establishing of cardiopulmonary bypass for Minimally Invasive Cardiac Surgery. It is routine procedure for this type of cardiac surgery.
Study: NCT03654105

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: spirometry with CO test
Description: spirometry with CO test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: spirometry with CO test
Description: spirometry with CO test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: spirometry with CO test
Description: spirometry with CO test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anthropometic data collection
Description: anthropometic data collection

Intervention type: OTHER
Group type: OTHER
Intervention: anthropometic data collection
Description: anthropometic data collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anthropometic data collection
Description: anthropometic data collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anthropometic data collection
Description: anthropometic data collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood test
Description: blood test to assess the metabolic and inflammatory profile

Intervention type: OTHER
Group type: OTHER
Intervention: blood test
Description: blood test to assess the metabolic and inflammatory profile

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood test
Description: blood test to assess the metabolic and inflammatory profile

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood test
Description: blood test to assess the metabolic and inflammatory profile
Study: NCT04592627

Intervention type: OTHER
Intervention: Simulated home environment visit
Description: During the simulated home environment visit participants will 1) participate in a simulated University of Texas (UT) Physicians Stroke Outpatient Clinic telemedicine visit using an iPAD during which participants will be audio- and visually-recorded in order for the research team to collect raw facial expression data; 2) be instructed to complete a series of activities of daily living (e.g., sitting down and brushing hair) during which participants will be audio- and visually-recorded in order for the research team to collect raw body motion tracking data; and 3) complete a participant satisfaction survey via a REDCap link and participate in an audio-recorded, semi-structured interview (e.g., asking the participants thoughts on privacy considerations related to future use of the facial expression and body motion technology in a home environment) with members of the research team.
Study: NCT03453281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection [Eylea]
Description: Intravitreal Aflibercept injections were performed by vitreoretinal consultant at the place of study.
Study: NCT04383340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother-Infant Transaction Program
Description: Parent sensitivity training for mothers of premature infants
Study: NCT01420900

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THA with ABG II / Trident
Description: Surgery with total hip arthroplasty in the form of ABG II / Trident

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THA with CLS / Trilogy
Description: Surgery with total hip arthroplasty in the form of CLS / Trilogy
Study: NCT03648684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caffeine-Based Expectancy Challenge
Description: Intervention to alter expectancies and encourage safe drug substitution (harm reduction plus expectancy modification)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Based Expectancy Challenge
Description: Intervention to alter expectancies (expectancy modification only)
Study: NCT00439361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.0 mg/m\^2 by Vein Over 5 Seconds on Days 1 and 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 5 AUC by Vein Over 1 Hour On Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m\^2 By Vein Over 2 Hours On Days 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 5 Gm/m\^2 By Vein Continuous Infusion Over 24 Hours On Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 5 mg/m\^2 IV continuous Infusion over 24 Hours On Day 1; 2 Gm/m\^2 IV continuous infusion over 12 hours starting after completion of Ifosfamide + Mesna 24 hour continuous infusion
Study: NCT02934893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Management Clinic
Description: referral to medication management clinic from primary care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication Management Clinic
Description: referral to medication management clinic from primary care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes+Me plus connected glucometer
Description: Use of software and medication modeling tool as add on to medication management standard of care
Study: NCT00731588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transfused Biotin RBCs - Adults Phase I
Description: A 3 mL venous blood sample is obtained. 250 mL of blood will be drawn to a blood collection bag containing the anticoagulant CPD. Separate equal volumes of RBCs are labeled with up to five different densities of biotin. The biotinylated RBCs are resuspended in autologous plasma to achieve a 60 to 70% hematocrit. An IV is inserted for the reinfusion of the biotinylated RBCs. Three mL aliquots of blood are sampled at 5, 10, 20, and 60 minutes after infusion. The subject returns \~24 hours and 3 days after the RBC infusion to obtain a 3 mL venous blood sample. Subjects return for weekly 3 mL blood sampling.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transfused Biotin RBCs - Infants Phase II
Description: After the infant's clinical care team decides that a RBC transfusion is needed, a 15mL/kilogram of body weight is ordered. Transfusion will be given in 2 parts: 1) approximately 80% of the total transfusion to be transfused over 3-4 hours and 2) approximately 20% of the total transfusion will be marked with biotin to be transfused upon completion of the first part. The bedside nurse maintains constant observation of the infant as appropriate for the infant's condition, assessing for signs and symptoms of a transfusion reaction.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transfused Biotin RBCs - Infants Phase III
Description: Phase III (infants) to be determined upon completion of Phase II (infants).
Study: NCT00710814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leptin
Description: Leptin self-administered subcutaneously at 0.05 mg/kg body weight twice each day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leptin
Description: Leptin self-administered subcutaneously at 0.05 mg/kg body weight twice each day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile water equal in volume to that of the metreleptin dose calculated for each individual self-administered subcutaneously twice each day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile water equal in volume to that of the metreleptin dose calculated for each individual self-administered subcutaneously twice each day
Study: NCT01913288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological Maternal Sounds

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Biological Maternal Sounds
Study: NCT02518685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: The goal of lifestyle modification counseling is to promote adherence to a reduced calorie diet, increased physical activity and to recommend behavioral modification strategies.
Study: NCT00193778

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery for breast cancer
Description: This group will receive standard loco-regional treatment i.e. surgery (modified radical mastectomy (MRM)/ Simple SMAC/BCT) +/- radiotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Loco-regional treatment
Description: This group will not receive any loco-regional treatment
Study: NCT00601354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion regulation group therapy
Description: Emotion regulation guided self-help group therapy involves twelve 2-hour sessions of guided self-help group psychotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat/alli program
Description: The orlistat/alli program involves taking 60 mg orlistat three times a day and participating in the alli program, a comprehensive behavioral weight loss program with online access.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat/alli program
Description: The orlistat/alli program involves taking 60 mg orlistat three times a day and participating in the alli program, a comprehensive behavioral weight loss program with online access.
Study: NCT04812587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention program
Description: The experimental group will receive a 12-week combined exercise intervention program with extra emphasis on balance, muscle strength, and walking ability which involved two 2-hour sessions once per week.
Study: NCT03368989

Intervention type: DRUG
Intervention: Radium-223 dichloride
Description: Previously known as Alpharadin, Radium-223 dichloride is a calcium-mimetic, alpha emitting radiopharmaceutical, which introduces double-stranded DNA breaks in metastatic cancer cells.
Study: NCT05572411

Intervention type: OTHER
Intervention: GAITRite Electronic Walkway
Description: Participants will be asked to walk across the electronic walkway to record information relating to their gait pattern. Depending on the age and compliance of the participant, they will be asked to complete 3 passes at 3 speeds, preferred, fast and slow.
Study: NCT00434161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palifermin before only
Description: One bolus IV injection at 60 μg/kg/day, on Days 6, 5 \& 4 days before-high dose chemotherapy and one bolus IV injection at 60 μg/kg/day of matched placebo on days 0, 1 \& 2 days after-high dose chemotherapy. Minimum of 4 days between before-chemotherapy and after-transplantation dosing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One bolus IV injection at 60 μg/kg/day of matched placebo on Days 6, 5 \& 4 (before-high dose chemotherapy) and on Days 0, 1 \& 2 (after-high dose chemotherapy).~Minimum of 4 days between pre-chemotherapy and post-transplantation dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palifermin before and after
Description: One bolus IV injection at 60 μg/kg/day, on Days 6, 5 \& 4 (before-high dose chemotherapy) and on Days 0, 1 \& 2 (after-high dose chemotherapy).~Minimum of 4 days between before-chemotherapy and after-transplantation dosing.
Study: NCT00279448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: On tablet of 25 mg per day during 5 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen
Description: Two tablets of tamoxifen 10 mg per day during 2.5 to 3 years followed by one tablet of exemestane 25 mg per day during 2 to 2.5 years for a total duration of 5 years of treatment
Study: NCT03168074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: Eligible patients will be treated with approximately 2 weeks of single agent lenvatinib (range 10-28 days, depending on the date of breast cancer surgery; last dose of lenvatinib to be administered no later than 48 hours before surgery in patients who are planned to receive ≤14 days lenvatinib, and no later than 120 hours before surgery in patients who are planned to receive 15-28 days lenvatinib).Tissue sections from the pre-treatment and post-treatment tumor will be collected for biomarker analysis. Pre- and post-treatment ultrasound will be used to document the size of the target lesions.
Study: NCT05408286

Intervention type: BEHAVIORAL
Intervention: administration of questionnaires
Description: administration of questionnaires
Study: NCT04750005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listerine Cool Mint
Description: Participants use 20 mL of Listerine cool mint mouth rinse for 30 sec after brushing twice a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listerine Cool Mint
Description: Participants use 20 mL of Listerine cool mint mouth rinse for 30 sec after brushing twice a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reach Unflavored Waxed Dental Floss
Description: Participants after brushing for 1 minute, rinse mouth with water and FLOSS once a day in first use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reach Unflavored Waxed Dental Floss
Description: Participants after brushing for 1 minute, rinse mouth with water and FLOSS once a day in first use.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: American Dental Association (ADA) Ref Toothbrush
Description: Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: American Dental Association (ADA) Ref Toothbrush
Description: Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: American Dental Association (ADA) Ref Toothbrush
Description: Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: American Dental Association (ADA) Ref Toothbrush
Description: Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
Study: NCT03081715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PD-1 Knockout T Cells
Description: Programmed cell death 1(PD-1) gene will be knocked out by CRISPR Cas9
Study: NCT02618564

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sennosides
Description: Each group will be assigned different doses of sennosides and varying times of administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sennosides
Description: Each group will be assigned different doses of sennosides and varying times of administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sennosides
Description: Each group will be assigned different doses of sennosides and varying times of administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sennosides
Description: Each group will be assigned different doses of sennosides and varying times of administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sennosides
Description: Each group will be assigned different doses of sennosides and varying times of administration
Study: NCT01029678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin IV
Description: Cisplatin IV 30 mg/m2/ (Day 1, Day 8, Day 15, Day 22, Day 29, Day 36)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine per os 30 mg/m2/(day1, day8, day15, day22, day29, day36

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 66Gy, 33 fractions, 6 week
Study: NCT04383340

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Standard hospital care and parental support
Study: NCT03738098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants will receive traditional genetic counseling (GC) for the Baseline and Return of Results (ROR1) visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants will receive traditional genetic counseling (GC) for the Baseline and Return of Results (ROR1) visits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GUÍA
Description: GUÍA for the ROR1 visit.
Study: NCT00143598

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Knee-length, graduated elastic compression stocking
Description: Worn daily for 2 years, 30-40 mm Hg

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Knee-length, placebo stocking
Description: Worn daily for two years
Study: NCT00801086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7% (w/v) Tempol alcohol-based gel (MTS-01)
Description: 200mL gel applied daily prior to radiation dose and removed immediately thereafter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: alcohol-based gel
Description: 200mL gel applied daily prior to radiation dose and removed immediately thereafter